soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo SOUL Trial (NEJM 2025): Oral

Systemic administration of Rs-NPs may prove insufficient for delivering the drug directly to adipocytes within WAT

And whats clear, and fascinating, is that the side effects Im hearing about are evolving

Semaglutide, conversely, stimulates GLP-1 receptors in pancreatic beta cells to increase insulin secretion in response to meals and reduces glucagon secretion when glucose levels drop

However, the calorie-burning effect of herbal teas remains smalltypically fewer than 100 extra calories burned per day even under optimal conditions

Choosing Between Semaglutide and Lipotropic Approaches Your decision between semaglutide and lipotropic injections should align with your weight loss goals, baseline metabolic health, and underlying genetic predispositions